Abstract
The use of immunosuppressive therapy may be associated with significant toxicity. The aim of this study was to investigate the effect of cyclosporine A (CsA) in murine model of experimental colitis. Experimental colitis was induced in NMRI mice using an enema of 0.2% solution of dinitrofluorobenzene, combined with skin sensitization. After inducing colitis, experimental groups of animals were treated with CsA (1, 3, 5, 10, 25, 50 mg/kg/day) intraperitoneally (i.p.) or intracolonically (i.c.), and control groups were treated with phosphate-buffered saline intraperitoneally or intracolonically, respectively. Colonic inflammatory changes were assessed using a histopathologic score of 0–30, and pooled whole blood samples were processed with monoclonal antibodies for cyclosporine concentration. In addition, two groups of animals with experimental colitis were treated intraperitoneally or intracolonically with 3 mg/kg/day of CsA, and the colons were also taken for immunohistochemistry for CD25. CsA diminished the extent of colitis in groups treated with 3, 5, 10, or 25 mg/kg intraperitoneally or intracolonically, and in groups treated with 1 and 50 mg/kg intracolonically (P < 0.05). The effect of intracolonic application of CsA was not related to whole blood cyclosporine concentrations. In addition, the effect of CsA at 3 mg/kg, applied intraperitoneally or intracolonically was, in part, expressed in decreasing the numbers of CD25+ cells within colonic mucosa/submucosa (P < 0.05). In conclusions, the results of this study indicate the possibility of intracolonic application of cyclosporine in order to widen the therapeutic window for effective, but possibly toxic drug, such as cyclosporine.
Similar content being viewed by others
REFERENCES
Present DH, Rutgeerts P, Targan S, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398–1405, 1999
Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB: Thalidomide therapy for patients with refractory Crohn's disease: An open label trial. Gastroenterology 117:1271–1277, 1999
Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117:1278–1287, 1999
Brynskow J: Cyclosporine for inflammatory bowel disease: Mechanisms and possible actions. Scand J Gastroenterol 28:849–857, 1993
Strober W, Ehrhardt RO, Ludviksson BR: Inflammatory bowel diseases: A breakdown of central and peripheral immunological homeostasis. In Inhibition and Modulation of gastrointestinal inflammation. Falk Symposium 104. A Stallmach, M Zeitz, W Strober, TT MacDonald, H Lochs (eds). Dordrecht, Kluwer Academic Publishers, 1998, pp 97–110
Brki? T, Bani? M, Ani? B, Grabarevi? Ž, Rotkvi? I, Artukovi? B, Duvnjak M, Sikiri? P, Troskot B, Hernandez DE: A model of inflammatory bowel disease induced by 2,4-dinitrofluorobenzene in previously sensitized BALB/c mice. Scand J Gastroenterol 27:184–188, 1992
Bani? M, Brki? T, Ani? B, Rotkvi? I, Grabarevi? Ž, Duvnjak M, Troskot B, Mihatov Š: Effect of methylprednisolone on small bowel, spleen and liver changes in murine model of inflammatory bowel disease. Aliment Pharmacol Ther 7:201–206, 1993
Shaw LM, Yatscoff RW, Bowers LD: Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem 36:1841–1846, 1990
Selby WS, Janossy G, Boffil M, Jewell DP: Intestinal lymphocyte subpopulations in inflammatory bowel disease by immunohistochemical and cell isolation techniques. Gut 25:32–40, 1984
Vilaseca J, Salas A, Guarner F, Rodrigez R, Martinez M, Malagelada J-R: Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 31:539–544, 1990
Velja?a M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglieta A: BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. JPET 272:417–422, 1995
Dawson-Saunders B, Trapp RG: Basic and Clinical Biostatistics. London, Prentice-Hall, 1994
Fukushima K, Masuda T, Ohtani H, Sasaki I, Funayama Y, Matsuno S, Nagura H: Immunohistochemical characterization, distribution and ultrastructure of lymphocyte bearing T-cell receptor gamma/delta in inflammatory bowel disease. Gastroenterology 101:670–678, 1991
Kim HS, Berstad A: Experimental colitis in animal models. Scand J Gastroenterol 27:529–537, 1992
Elson CO, Sartor RB, Tennyson GS, Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367, 1995
Elson CO: Experimental models of intestinal inflammation. New insights into mechanisms of mucosal homeostasis: In PL Ogra, J Mestecky, ME Lamm, W Strober, J Bienenstock, JR McGhee (eds). Mucosal Immunology. San Diego, Academic Press, 1999, pp 1007–1024
Wallace JL, MacNaughton WK, Morris GP, Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29–36, 1989
Higa A, McKnight GW, Wallace JL: Attenuation of epithelial injury in acute experimental colitis by immunomodulators 239:171–176, 1993
Morris, GP, Beck PL, Herridge MS, Depew WT, Sewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in rat colon. Gastroenterology 96:795–803, 1989
Suya H, Fujioka A, Pincelli C, Fukuyama K, Epstein WL: Skin granuloma in mice immunosupressed by cyclosporine. J Invest Dermatol 90:430–433, 1988
Braunstein J, Autschbach F, Sido B, Nebl G, Schroeder A, Samstag Y, Meuer SC: Insensitivity towards inhibition by cyclosporine A, rapamycin and tacrolimus in human intestinal lamina propria T-lymphocytes. In Inhibition and Modulation of Gastrointestinal Inflammation. Falk Symposium 104. A Stallmach, M Zeitz, W Strober, TT MacDonald, H Lochs (eds). Dordrecht, Kluwer Academic Publishers, 1998, pp 97–110
Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–1845, 1994
Feagan BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R, Valberg B, Irvine J, for Canadian Crohn's Relapse Prevention Trial Investigators: Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 330:1846–1851, 1994
Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Bowel Dis 1:48–63, 1995
Sorokin R, Kimura H, Schroeder K, Wilson DH, Wilson DB: Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus and potency estimates of autoimmune lymphocytes in drug treated rats. J Exp Med 164:1615–1625, 1986
Bucy PR, Xu XY, Li J, Huang GQ: Cyclosporine A-induced autoimmune disease in mice. J Immunol 151:1039–1050, 1993
Ottenhof THM: Selective modulation of T-cell responses in autoimmunitiy and cancer. Immunol Today 17:54–55, 1996
Sandborn WJ, Stron RM, Forland SC, Chase RE, Cutler RE: The pharmacokinetics and colon tissue concentrations of cyclosporine after IV, oral and enema administration. J Clin Pharmacol 31:76–80, 1991
Gurbindo C, Russo P, Sabbah S, Lohoues MJ, Seisman E: Interleukin-2 activity of colonic lamina propria mononuclear cells in a rat model of experimental colitis. Gastroenterology 104:964–972, 1993
Brynskow J: Cyclosporine/Tacrolimus in Crohn's disease: acute and chronic. Falk symposium 119. Immunosuppression in inflammatory bowel disease—standards—new developments—future trends. Abstract Book, 2000, p 38
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Banić, M., Anić, B., Brkić, T. et al. Effect of Cyclosporine in a Murine Model of Experimental Colitis. Dig Dis Sci 47, 1362–1368 (2002). https://doi.org/10.1023/A:1015339018181
Issue Date:
DOI: https://doi.org/10.1023/A:1015339018181